Skip to main content
Journal cover image

A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer

Publication ,  Journal Article
Beeram, M; Tolaney, SM; Beck, JT; Dickler, MN; Conlin, AK; Dees, C; Helsten, TL; Conkling, PR; Edenfield, WJ; Richards, DA; Kambhampati, SRP ...
Published in: Annals of Oncology
October 1, 2016

Duke Scholars

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi556

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beeram, M., Tolaney, S. M., Beck, J. T., Dickler, M. N., Conlin, A. K., Dees, C., … Goetz, M. P. (2016). A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology, 27, vi556. https://doi.org/10.1093/annonc/mdw435.08
Beeram, M., S. M. Tolaney, J. T. Beck, M. N. Dickler, A. K. Conlin, C. Dees, T. L. Helsten, et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” Annals of Oncology 27 (October 1, 2016): vi556. https://doi.org/10.1093/annonc/mdw435.08.
Beeram M, Tolaney SM, Beck JT, Dickler MN, Conlin AK, Dees C, et al. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 2016 Oct 1;27:vi556.
Beeram, M., et al. “A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer.” Annals of Oncology, vol. 27, Oct. 2016, p. vi556. Scopus, doi:10.1093/annonc/mdw435.08.
Beeram M, Tolaney SM, Beck JT, Dickler MN, Conlin AK, Dees C, Helsten TL, Conkling PR, Edenfield WJ, Richards DA, Kambhampati SRP, Costigan TM, Chan E, Pant S, Kalinsky K, Burris HA, Becerra CH, Rexer BN, Puhalla SL, Goetz MP. A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer. Annals of Oncology. 2016 Oct 1;27:vi556.
Journal cover image

Published In

Annals of Oncology

DOI

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

27

Start / End Page

vi556

Related Subject Headings

  • Oncology & Carcinogenesis
  • 1112 Oncology and Carcinogenesis